Niche Therapeutics Eligo pursues a novel class of microbiome precision editing therapeutics with a topical gene delivery platform that enables local production of biologics by skin resident bacteria, creating business development opportunities with dermatology clinics, skincare brands, and biotech partners for proof of concept studies and licensing collaborations.

Funding Momentum A government grant to accelerate scaling of the topical delivery platform signals validation and opens doors for grant funded pilots, public private partnerships, and collaborative R&D engagements with research institutes and pharma.

Agile Team With a small to mid sized team, Eligo can leverage partner ecosystems for faster development, manufacturing support, and regulatory work, making it suitable for contract R&D, licensing deals, and joint development arrangements.

EU Market Access Based in Paris with local government backing, the company is well positioned to engage European cosmetic and dermatology markets, clinical researchers, and venture partners seeking EU focused collaborations, pilots, and regulatory strategy.

Differentiated Positioning Eligo’s approach of local biologics production by skin resident bacteria offers a unique value proposition versus broader microbiome players, enabling partnerships with skincare brands, dermatology clinics, and consumer health companies to explore topical therapies and precision microbiome editing.